245 related articles for article (PubMed ID: 31599852)
21. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
[TBL] [Abstract][Full Text] [Related]
22. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW
Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871
[TBL] [Abstract][Full Text] [Related]
23. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.
Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA
Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.
Gauthier A; Breuer J; Carrington D; Martin M; Rémy V
Epidemiol Infect; 2009 Jan; 137(1):38-47. PubMed ID: 18466661
[TBL] [Abstract][Full Text] [Related]
25. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.
Coretti S; Codella P; Romano F; Ruggeri M; Cicchetti A
Int J Technol Assess Health Care; 2016 Jan; 32(4):233-240. PubMed ID: 27624398
[TBL] [Abstract][Full Text] [Related]
26. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
[TBL] [Abstract][Full Text] [Related]
27. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
Curran D; Hunjan M; El Ghachi A; El-Hahi Y; Bianco V; Ferreira G
BMJ Open; 2019 Aug; 9(8):e023502. PubMed ID: 31462457
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
Szucs TD; Kressig RW; Papageorgiou M; Kempf W; Michel JP; Fendl A; Bresse X
Hum Vaccin; 2011 Jul; 7(7):749-56. PubMed ID: 21606685
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
Van Oorschot D; Anastassopoulou A; Poulsen Nautrup B; Varghese L; von Krempelhuber A; Neine M; Lorenc S; Curran D
Hum Vaccin Immunother; 2019; 15(1):34-44. PubMed ID: 30130448
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Rothberg MB; Virapongse A; Smith KJ
Clin Infect Dis; 2007 May; 44(10):1280-8. PubMed ID: 17443464
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
35. Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States.
Curran D; La EM; Salem A; Singer D; Lecrenier N; Poston S
Hum Vaccin Immunother; 2022 Dec; 18(1):2027196. PubMed ID: 35049412
[TBL] [Abstract][Full Text] [Related]
36. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
[TBL] [Abstract][Full Text] [Related]
37. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK.
Matthews I; Duong M; Parsons VL; Nozad B; Qizilbash N; Patel Y; Guimicheva B
PLoS One; 2020; 15(2):e0229224. PubMed ID: 32097441
[TBL] [Abstract][Full Text] [Related]
38. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain.
Cebrián-Cuenca AM; Díez-Domingo J; San-Martín-Rodríguez M; Puig-Barberá J; Navarro-Pérez J;
BMC Infect Dis; 2011 Nov; 11():302. PubMed ID: 22044665
[TBL] [Abstract][Full Text] [Related]
40. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]